TE Connectivity Ltd’s Q1 Orders were $3.8B, up 4% YoY

First Quarter Highlights Net sales were $3.83 billion, in line with guidance, essentially flat on a reported basis year over year and down 1% organically. GAAP diluted earnings per share

First Quarter Highlights

  • Net sales were $3.83 billion, in line with guidance, essentially flat on a reported basis year over year and down 1% organically.
  • GAAP diluted earnings per share (EPS) from continuing operations were $5.76, including a one-time tax-related benefit, and adjusted EPS were $1.84, up 20% year over year.
  • Orders were $3.8 billion, up 4% year over year, with year-over-year growth in all segments.
  • Operating margins were 18.2% and adjusted operating margins were 19.1%, up 290 basis points year over year.
  • Cash flow from operating activities was $719 million and free cash flow was $570 million, both first quarter records.
  • Deployed approximately $1 billion of capital in the quarter, including approximately $600 million returned to shareholders and approximately $350 million used for the acquisition of Schaffner.
Total
0
Shares
Related Posts
Read More

Genetic Technologies Announced Partnership With Siles Health to Bring GeneType Risk Test to 9 Clinics

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, a leading Obstetrics and Gynaecology practice, to implement geneType Multi-Risk Test as part of their commitment to remain at the forefront of contemporary personal

GENE

Read More

Sana Biotechnology Announces FDA Clearance oOf Investigational New Drug Application For SC291, A Hypoimmune-Modified, CD19-Directed Allogeneic CAR T Therapy, For Patients With Lupus Nephritis, Extrarenal Lupus, And ANCA-Associated Vasculitis

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearanceExpect to disclose initial clinical data next yearSEATTLE,

SANA